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Degradation and remodeling of the extracellular matrix by
matrix metalloproteinases (MMPs) plays important roles in
normal development, inflammation, and cancer. MMP-9 effi-
ciently degrades the extracellular matrix component gelatin,
and the hemopexin domain ofMMP-9 (PEX9) inhibits this deg-
radation. To study themolecular basis of this inhibition,we gen-
eratedGST fusion proteins containing PEX9 or truncated forms
corresponding to specific structural blades (B1–B4) of PEX9.
GST-PEX9 inhibited MMP-9-driven gelatin proteolysis, mea-
sured by gelatin zymography, FITC-gelatin conversion, and
DQ-gelatin degradation assays. However, GST-PEX9 did not
prevent the degradation of other MMP-9 substrates, such as a
fluorogenic peptide, B crystalline, or nonmuscular actin.
Therefore, PEX9 may inhibit gelatin degradation by shielding
gelatin and specifically preventing its binding to MMP-9.
Accordingly, GST-PEX9 also abolished the degradation of
gelatin by MMP-2, confirming that PEX9 is not an MMP-9
antagonist. Moreover, GST-B4 and, to a lesser extent,
GST-B1 also inhibited gelatin degradation by MMP-9, indi-
cating that these regions are responsible for the inhibitory
activity of PEX9. Accordingly, ELISAs demonstrated that
GST-B4 and GST-B1 specifically bound to gelatin. Our
results establish new functions of PEX9 attributed to blades
B4 and B1 and should help in designing specific inhibitors of
gelatin degradation.
The matrix metalloprotease (MMP)5 family comprises more
than 25 Zn2-dependent proteases that mainly degrade extra-
cellularmatrix components but also signalingmolecules,mem-
brane receptors, and intracellular and nuclear proteins (1–6).
MMPs play roles in normal developmental processes (embryo-
genesis, wound healing, and cell mobilization), as well as in
many pathological conditions, such as cancer and inflamma-
tory reactions (7, 8). Indeed, the catalytic regions ofMMPs have
been tested as targets for cancer drugs, but most clinical trials
failed (9). This was probably due to the high homology of these
regions across MMPs, with the consequent low selectivity of
the inhibitors and the induction of secondary effects of the
drugs.
MMP-9, also known as gelatinase B, is one of the most com-
plex members of the MMP family. In contrast to gelatinase A
(MMP-2), which is constitutively expressed, MMP-9 is highly
regulated by numerous agonists/antagonists (10). Like other
MMPs, MMP-9 is a multidomain enzyme composed of a
prodomain, a catalytic domain, and a carboxyl-terminal
hemopexin domain. Both MMP-2 and MMP-9 possess a
domain with three fibronectin type II homology repeats that
yield high affinity binding to gelatins. Only MMP-9 contains a
serine-, threonine-, and proline-rich O-glycosylated domain,
which confers high flexibility to the enzyme (10).
The hemopexin domain ofMMP-9 (PEX9) and otherMMPs
consists of four blade -propeller structures (blades 1, 2, 3, and
4) (11). PEX9 is responsible for the interactions ofMMP-9 with
many molecules, including substrates, cell receptors, such as
integrins and CD44, and tissue inhibitors of MMPs (12–15).
PEX9 also contributes toMMP-9 trimerization (16). Because of
these properties and the low homology with the hemopexin
domains of other MMPs (25–30% identical residues) (12),
PEX9 is revealed as an interesting target to increase the selec-
tivity of MMP-9 inhibitors.
Themain substrate ofMMP-9 is gelatin, the product of dena-
turation or degradation of collagen by collagenases (MMP-1,
MMP-8, and MMP-13). It was previously shown that the
murine PEX9 binds to gelatin, and a claim was made that PEX9
acts as an antagonist ofMMP-9 (17). This was based on the fact
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that PEX9 inhibited gelatinolysis in zymography assays, as well
as invasion of melanoma and colorectal cancer cells (17, 18). In
the present study, we have further investigated this, and we
demonstrate that human PEX9 inhibits gelatin degradation by
shielding gelatin and specifically preventing its interactionwith
active MMP-9. Moreover, we have identified the specific
regions of PEX9 responsible for the inhibitory effect, and we
show that PEX9 is not an antagonist of MMP-9 catalytic
activity.
Experimental Procedures
MEC-1 Cells and Transfectants—TheMEC-1 cell line, estab-
lished from a chronic lymphocytic leukemia (CLL) patient, was
purchased from theGermanCollection ofMicroorganisms and
Cell Cultures (DSMZ, Braunschweig, Germany). MEC-1 cells
stably expressing MMP-9 (MMP-9–MEC-1 cells) were gener-
ated by lentiviral transfection exactly as described (19). The
cells were maintained in Iscove’s modified Dulbecco’s medium
(Lonza, Basel, Switzerland), 10% fetal bovine serum.
Antibodies, Reagents, Proteins, and Peptides—Rabbit poly-
clonal antibodies to GST (sc-459) and MMP-9 (sc-6841-R)
were fromSantaCruz Biotechnology (SantaCruz, CA). Recom-
binant full-length human pro-MMP-9 was prepared as
reported (15). DQTM gelatin was purchased from Invitrogen,
and DQTM collagen and fluorogenic peptide (DNPPro-Cha-
Gly-Cys(Me)-His-Ala-Lys(N-Me-Abz)-NH2) were from Calbi-
ochem.MMP-2 and FITC-gelatin were fromMolecular Probes
(Eugene, OR). Human nonmuscle actin and subunit B-crys-
tallin recombinant proteinswere fromCytoskeleton, Inc. (Den-
ver, CO) and Enzo Life Sciences (Farmingdale, NY), respec-
tively. Pfu DNA polymerase was from Agilent Technologies
(Waldbronn, Germany).
Construction of Plasmids—The full-length human MMP-9
cDNA (cloned in pEGFP-N1) was obtained from Dr. Santos
Mañes (CentroNacional de Biotecnología,Madrid, Spain) (20).
The hemopexin domain cDNAwas amplified by PCR using the
following primers, custom-made by Sigma-Aldrich: forward,
5-GAATTCCCCTTTGAGTCCGGTGGACG-3 engineering
an internal EcoRI site (underlined in Table 1); and reverse,
5-CTCGAGCTAGTCCTCAGGGCACTGCA-3 containing
an internal XhoI restriction site. Amplification of DNAs was
performedwith the use of cloned PfuDNApolymerase, and the
resultant PCR fragments were inserted into the pGEX4T3 vector
(GEHealthcare Biosciences) to generate theGST-PEX9DNA.To
generate the PEX9 mutants, we performed similar protocols but
used theprimers indicated inTable 1. ForGST-B1,GST-B2,GST-
B3, and GST-B4, we engineered an internal EcoRI site in the for-
ward primers (GAATTC) and a XhoI site (CTCGAG) in the
reverse primers. For GST-B1, GST-B2, GST-B3, and GST-
B4, we designed internal primers with the initial and final
sequences of each removed blade, and we amplified the complete
construction from the GST-PEX9 plasmid. All obtained se-
quences were confirmed by DNA sequencing.
Expression and Purification of GST and GST Fusion Pro-
teins—Recombinant proteins were prepared as previously
described for GST and GST-PEX9 (14). Briefly, protein con-
structs were expressed in DH5 Escherichia coli competent
cells by induction with isopropyl-1-thio--D-galactopyrano-
side. Recombinant proteins were specifically induced in this
system and produced in sufficient amount for the desired
experimentation. Bacteria cultures were lysed by sonication in
1.5 M NaCl, 0.5 M Tris, 50 mM Na2 EDTA, 10% Triton, and
centrifuged. GST, GST-B1, GST-B2, and GST-B3 were soluble
in this buffer and were purified using a glutathione-agarose
matrix (Sigma-Aldrich). All other fusion proteins appeared in
inclusion bodies and were solubilized in PBS, supplemented
with 1% sarkosyl. These fusion proteins did not bind to gluta-
thione-agarose and were purified by SDS-PAGE and electro-
elution. Purity and identity of the proteins were confirmed by
SDS-PAGE andWestern blotting. Purified fusion proteinswere
renatured by extensive dialysis against PBS.
Cell Adhesion and Soluble Binding Assays—Adhesion assays
were performed in 96-well plates coated with 0.5% BSA or var-
ious concentrations of appropriate proteins. 1  105 MEC-1
cells were incubated with 1.4 ng/ml 2,7-bis(carboxyethyl)-
5(6)-carboxyfluorescein-acetoxymethyl ester (BCECF-AM;
Molecular Probes) for 20 min; suspended in RPMI 1640, 0.5%
BSA (adhesion medium); and added to the coated wells. After
60 min at 37 °C, attached cells were lysed with PBS, 0.1% SDS
and quantified using a fluorescence analyzer (BMG Labtech,
Offenburg, Germany). For binding assays in solution, 1  105
cells were incubated in 100 l of adhesion medium containing
the proteins under investigation and incubated for 30 min at
4 °C. After washing with ice-cold medium, the cells were incu-
bated with anti-GST polyclonal antibodies (30 min, 4 °C),
washed with cold PBS, and incubated (30 min, 4 °C) with Alexa
488-labeled secondary antibodies. Surface-bound proteins
were analyzed by flow cytometry.
Incubation of PEX9 Proteins with ActiveMMP-9—MMP-9 in
50 mM Tris, 150 mMNaCl, 5 mM CaCl2, 0.01% Tween 20 buffer
was activated with the catalytic domain of MMP-3 (Millipore)
at aMMP-3:MMP-9 ratio of 1:100. GST-PEX9 (1g) was incu-
bated with activeMMP-9 for 100 min, and aliquots of the reac-
tion were taken every 10 min. For the analysis of nonmuscular
actin and B-crystallin cleavage, 2 g of the recombinant pro-
TABLE 1
Primers designed to generate the variousGST-PEX9 recombinant pro-
teins
F, forward; R, reverse.
Protein Primers (53 3)
PEX9 F GAATTCCCCTTTGAGTCCGGTGGACG
PEX9 R CTCGAGCTAGTCCTCAGGGCACTGCA
B1B2 F GAATTCCCCTTTGAGTCCGGTGGACG
B1B2 R CTCGAGTCACCTGGGCCACGTC
B3B4 F GAATTCAGCCGACGTGGCCCAG
B3B4 R CTCGAGCTAGTCCTCAGGGCACTGCA
B1 F GAATTCCCCTTTGAGTCCGGTGGACG
B1 R CTCGAGTCCAGCTTGCGGGGCA
B2 F GAATTCACCGCTGGACTCGGTCTTTG
B2 R CTCGAGTCACCTGGGCCACGTC
B3 F GAATTCAGCCGACGTGGCCCAG
B3 R CTCGAGTCCAAAGGCACCCCGG
B4 F GAATTCTTTGGACACGCACGACG
B4 R CTCGAGCTAGTCCTCAGGGCACTGCA
B1 F TCTAGAGCTGGACTCGGTCTTTGA
B1 R TCTAGAGATCCACGCGGAACCAGAT
B2 F TCTAGAAGTGGCAGGGGGAAGATG
B2 R TCTAGAGCCACTTGTCGGCGATA
B3 F TCTAGAGACGTCTTCCAGTACCGAGAG
B3 R TCTAGAGCCCAGCTTGTCCAGA
B4 F TCTAGAGACTGACTGACGATCTGCCTC
B4 R TCTAGATCCGGGGATCCACCAT
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teins were incubated with active MMP-9 (enzyme:substrate
ratio of 1:20) at 37 °C for 2, 8, and 24 h in the presence or
absence of GST-PEX9. The incubated fractions were analyzed
on 12% SDS-PAGE gels and visualized by staining with Coo-
massie Brilliant Blue R-250 (Sigma).
Gelatin Zymography Analysis—Samples of 20 ng of recombi-
nant purified MMP-9 were analyzed on 7.5% polyacrylamide
gels containing 0.1% gelatin (Sigma). The amount of the
MMP-9 added in the gel was within the linear range of the
zymogram, and this was evaluated by testing a dilution series of
MMP-9 by zymography analysis. After electrophoresis, the gels
were rinsed three times for 30 min in 2.5% Triton X-100 and
once for 30 min in distilled water, followed by overnight incu-
bation in 50 mM Tris, pH 7.5, 200 mM NaCl, 10 mM CaCl2 at
37 °C. To analyze the effect of GST-PEX9 recombinant pro-
teins, mutant proteins were added to the incubation buffers
overnight at a final concentration of 0.4 M. The gels were
stained with 0.2% Coomassie Blue, and areas of gelatinolysis
were visualized as transparent lysis zones. The bands were
quantitated on a densitometer (Molecular Dynamics) using the
Quantity-OneTM program (Bio-Rad). Control MMP-9 levels
were normalized to 100%.
FITC-Gelatin Degradation Assay—60 nM activated MMP-9
in 50 mM Tris, 150 mMNaCl, 5 mM CaCl2, 0.01% Tween 20 was
added to 96 FITC-gelatin-coated wells (100 g/ml) in the
absence or presence of 0.4 M recombinant GST-PEX9 pro-
teins. After 24 h at 37 °C, the wells were washed with PBS, and
fluorescence was measured using a fluorescence analyzer
(BMGLabtechnologies,OffenburgGermany). The background
fluorescence of the conditioned medium added to unlabeled
gelatin-coated wells was subtracted from all values. To analyze
the capacity of the GST-PEX9 proteins on gelatin degradation
by leukemic cells, 96-well plates were coated with 100 g/ml of
FITC-labeled gelatin and the various GST-PEX9 proteins and
fixed with 0.5% glutaraldehyde. After washing with PBS, 70%
ethanol/PBS and medium, 1 105 MMP-9–MEC-1 cells were
added to the wells. After 24 h, the cells were removed with
several washing steps, and the fluorescence was measured.
DQ-Gelatin or Fluorigenic Peptide Degradation Assay—A
DQ-gelatin degradation assay was performed as previously
described (21). Briefly, to measure the degradation in fluores-
cence units, 0.1 nM of active MMP-9 was added to a solution of
2.5g/ml of DQ-gelatin in a black 96-well plate. To analyze the
maximal enzyme velocity in these assays, several concentra-
tions of the DQ-gelatin substrate (20, 10, 5, 2.5, 0.75, 0.5, and
0.25g/ml) were added to the 96-well plate. To test the effect of
the GST-PEX9 constructs, 0.4 M of the recombinant proteins
were added to the wells. The plates were immediately placed in
the fluorescence reader (FL600microplate fluorescence reader;
Biotek, Highland Park, IL), and fluorescence was measured
every 10 min for 2 h at 37 °C (excitation, 485 nm; emission, 530
nm). All of the data were corrected by subtraction of the nega-
tive controls. In all the experiments, themaximal velocity of the
enzyme was the velocity observed during the first 10 min of the
assay. Graphs and calculations were obtained with Prism 5
(GraphPad Software, Inc.).
To test the degradation of a small fluorogenic peptide we
used DNPPro-Cha-Gly-Cys(Me)-His-Ala-Lys(N-Me-Abz)-
NH2 (excitation, 365 nm; emission, 450 nm). This substrate is
cleaved by MMP-9 into a single cleavage product: Dnm-Pro-
Cha-Gly (22). ActivatedMMP-9 was used at a concentration of
1 nM, and the fluorigenic peptide was used at 10 g/ml. Fluo-
rescence wasmeasured every 10min for 2 h in the fluorescence
reader.
ELISA—High binding 96-well plates were coatedwith 5g of
gelatin overnight at 4 °C. After washing, recombinant proteins
were added at a final concentration of 0.4M and incubated for
1 h at 37 °C; then the plates were washed, and anti-GST poly-
clonal antibody at 5 g/ml was added to the wells. After incu-
bation for 1 h at 37 °C, the plate was incubated with secondary
anti-rabbit HRP antibody for 30 min, washed, and developed.
Results
TheHuman proMMP-9HemopexinDomain Inhibits Gelatin
Degradation by MMP-9—Roeb et al. (17) previously showed
that the murine PEX9 domain inhibits MMP-9 activity in gela-
tin zymography assays. To investigate the molecular basis of
this observation, we prepared a fusion protein containing GST
and human PEX9 (residues 508–707 of proMMP-9; Fig. 1A).
After purification, the GST-PEX9 protein ran as a single
50-kDa band in SDS gels, and its identity was confirmed by
Western blotting analysis with an anti-MMP-9 antibody (Fig.
1B). Recombinant GST alone was also prepared by bacterial
expression (Fig. 1B) and was used as control. We previously
showed that the resulting GST-PEX9 protein, but not GST
alone, mediates CLL cell adhesion and soluble cell binding via
specific cell surface receptors (14, 23). GST-PEX9 also specifi-
cally inhibits chemotaxis and transendothelialmigration of leu-
kemic B cells and induced survival signals upon binding to
41 integrin (14, 23). Therefore, the purified GST-PEX9 pro-
tein fully retained its biological activities and was suitable for
further functional analyses.
In initial experiments, we determined whether MMP-9 was
able to cleave GST-PEX9. The GST-PEX9 protein (1 g) was
incubated with active MMP-9 (1 nM), and samples were taken
every 10 min for a time interval of 100 min. Analyses by SDS-
PAGE followed by protein staining with Coomassie Blue
showed that MMP-9 did not degrade the GST-PEX9 protein
(Fig. 1C). With the knowledge that GST-PEX9 remained intact
in the presence of active MMP-9, we analyzed the effect of
GST-PEX9 on gelatin degradation by MMP-9, using three dif-
ferent techniques: gelatin zymography, degradation of FITC-
gelatin in 96-well plate format, and DQ-gelatin degradation
assay. In all these experiments, we also tested the effect of puri-
fied GST as negative controls.
Gelatin zymography analyses demonstrated that adding
GST-PEX9 (0.4M) reduced gelatin degradation byMMP-9 by
50% (Fig. 1D), whereas GST had no effect. To study whether
GST-PEX9 inhibited the degradation of FITC-gelatin, GST-
PEX9 was incubated with active MMP-9 in microtiter plate
wells coated with FITC-gelatin, and the fluorescence was mea-
sured after 24 h. GST-PEX9, but not GST, significantly de-
creased gelatin degradation by MMP-9 (average 50% decrease)
(Fig. 1E). The inhibitory function of PEX9 was also demon-
strated with a dye-quenched gelatin (DQ-gelatin) degradation
assay (21). As shown in Fig. 1F, GST-PEX9 significantly
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reduced the level of fluorescence in a time-dependent manner,
during the 120 min of the assay. GST-PEX9 also reduced the
MMP-9 enzyme velocity in this assay, whereas no inhibition
was seen after incubation with GST (Fig. 1G). Altogether, these
results established that the human PEX9 domain inhibits the
degradation of gelatin by MMP-9, in agreement with previous
results with murine PEX9 (17).
The PEX9 Domain Does Not Act as an MMP-9 Antagonist—
To determine whether PEX9 is an MMP-9 antagonist and
blocks its catalytic activity or, alternatively, binds to gelatin and
prevents its degradation byMMP-9,we tested differentMMP-9
substrates and different gelatinases. In contrast to the inhibi-
tory effect on the degradation ofmacromolecular gelatin (Fig. 1,
D–G), GST-PEX9was unable to block the proteolysis of a small
DQ-fluorogenic peptide (FP) by MMP-9 (Fig. 2A). Moreover,
the enzyme velocity from the same assays was similar in the
presence or absence of GST-PEX9 (Fig. 2A).
We next analyzed whether GST-PEX9 affected the proteo-
lytic activity of MMP-9 on other MMP-9 substrates, such as
B-crystallin (24) and nonmuscular actin (6). To this end, we
performed kinetic assays incubating B-crystallin and actin
with active MMP-9 in the presence or absence of GST-PEX9
and evaluated protein degradation at 2, 8, and 24 h. As shown in
Fig. 2B, the presence of PEX9 did not influence the degradation
of actin by MMP-9 and only minimally delayed the proteolysis
of B-crystallin by this enzyme. In contrast to these results,
GST-PEX9 inhibited the degradation of DQ-collagen, another
MMP-9 substrate (Fig. 2C). Because DQ-gelatin can also be
degraded by MMP-2 (gelatinase A), we tested whether PEX9
also inhibited DQ-gelatin proteolysis by this enzyme. Fig. 2D
shows that GST-PEX9 was able to inhibit DQ-gelatin degrada-
tion by MMP-2 at similar levels as observed for MMP-9. Alto-
gether, these results corroborate the role of PEX9 as an inhibi-
tor of gelatin/collagen degradation and establish that PEX9 is
not a direct antagonist of the catalytic activity of MMP-9.
Blades 1 and 4 of the PEX9 Domain Are Responsible for the
Gelatin Degradation Inhibitory Activity of PEX9—The PEX9
domain contains a four-blade -propeller structure (11), sche-
matically shown in Figs. 1A and 3A. To define the region
involved in the inhibition of gelatin degradation, we prepared
two GST fusion proteins containing deletions of blades 3 and 4
(GST-B1B2 protein, proMMP-9 residues 508–613) or blades 1
and 2 (GST-B3B4 protein, proMMP-9 residues 609–707) (Fig.
3A). The purity of these proteins was confirmed by SDS-PAGE
analyses (Fig. 3B). We previously showed that purified GST-
B1B2 andGST-B3B4mediated CLL cell adhesion by binding to
CD44 and 41 integrin, respectively (14, 23). Moreover, we
also identified specific cell binding sequences in both proteins
(14, 23). The soluble proteins also specifically bound to cells and
inhibited CLL cell chemotaxis and transendothelial migration
(14, 23), thus confirming the retention of their biological activ-
ity. GST-B1B2 and GST-B3B4 were therefore tested as inhibi-
tors of gelatin degradation using different assays. In gelatin
zymography analysis, GST-PEX9, GST-B1B2, and GST-B3B4
(all at 0.4 M) inhibited gelatin degradation by 60, 35, and 40%,
respectively (Fig. 3C). Similar results were obtained with the
FIGURE 1. Effect of human GST-PEX9 on the degradation of gelatin by MMP-9. A, schematic drawing of the structural domains of proMMP-9. The four
structural blades of PEX9 (B1–B4) are indicated. The GST-PEX9 fusion protein prepared in this study contains amino acid residues 508–707 of human
proMMP-9. B, SDS-PAGE (10% acrylamide) andWestern blotting (WB) analyses of the purified GST and GST-PEX9 proteins. C, 1g of GST-PEX9 was incubated
with 1 nM active MMP-9 for the indicated times. The samples were analyzed by 10% SDS-PAGE and stained with Coomassie Blue (CB). D, gelatin zymography
analysis of 20 ng of MMP-9 (within the linearity of the assay) in the presence or absence of 0.4 M GST-PEX9. A representative zymography is shown. E, 60 nM
ofMMP-9was added to FITC-gelatin-coatedplates, in the absenceorpresenceof 0.4MGSTorGST-PEX9. After 24hat 37 °C, fluorescencewasdetermined, and
control (Ctrol) values were normalized to 100. F, effect of GST and GST-PEX9 (0.4 M) on the conversion of DQ-gelatin into fluorogenic gelatin. G, maximal
enzyme velocity as a function of the amount of substrate. The maximal velocity of each point is the first read time point at 10 min, and these measurements
were within the linearity of the assay. The bars represent standard deviation. AU, arbitrary units. **, p 0.01; ***, p 0.001.
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FITC-gelatin degradation assay. In this case, all three proteins,
GST-PEX9, GST-B1B2, and GST-B3B4 reduced the gelatino-
lytic activity of MMP-9 to 50%, compared with the control
(Fig. 3D). To further confirm these results, we analyzed the
inhibitory role of these recombinant proteins in the DQ-gelatin
degradation assay. Fig. 3E shows that GST-PEX9, GST-B1B2,
and GST-B3B4 similarly inhibited the velocity of the DQ-gela-
tin degradation by MMP-9. These data indicated that both
regions B1B2 andB3B4 appeared to contribute to the inhibitory
function of PEX9.
To identify the specific sequence within PEX9 that binds to
gelatin, we prepared alternative recombinant proteins, each
containing only one blade of the PEX9 domain (GST-B1, GST-
B2, GST-B3, and GST-B4) (Fig. 4, A and B). To first confirm
that these proteins retained their biological function, we ana-
lyzed their ability to mediate cell adhesion and soluble binding.
Fig. 4C shows that all four PEX9 blades mediated adhesion of
MEC-1 cells, whereas GST did not. As expected, the level of cell
adhesion to the individual blades was lower than adhesion to
the entire PEX9 domain (Fig. 4C). Additionally, these fusion
proteins, but not GST, were able to bind to MEC-1 cells in
suspension, as detected with an anti-GST antibody (Fig. 4D).
Having confirmed that the purified GST-B1, GST-B2, GST-
B3, andGST-B4proteinswere functional, we tested their ability
to block gelatin degradation. Fig. 4E shows for a representative
experiment how GST-B1 and GST-B4, but not GST-B2 or
GST-B3 (all at 0.4M), inhibited gelatin degradation in a gelatin
zymography assay. By comparison of the four single blade pro-
teins, GST-B4 was found to be more effective, blocking gelatin
degradation by 42%, whereas incubation with GST-B1 inhib-
ited by 25%. In parallel experiments, GST-PEX9 diminished the
degradation of gelatin by 60% (average of three independent
experiments) (Fig. 4C). We further compared the effect of the
recombinant proteins in a FITC-labeled gelatin degradation
assay. Again, GST-B4 was the most effective inhibitor, impair-
ing FITC-gelatin degradation by MMP-9 by 75%, whereas
GST-B1 diminished degradation by 25% (Fig. 4F). GST-B2 and
GST-B3 had no effect. We next tested the ability of these pro-
teins to inhibit DQ-gelatin degradation by MMP-9. In these
assays, GST-B4 blocked DQ-gelatin degradation by 63%,
whereas the effect of GST-B1 was lower and similar to that of
the entire GST-PEX9 (Fig. 4G).
The preceding results indicated that blades B1 and B4 were
the most effective inhibitory sequences in PEX9. To further
confirm this, we generated GST fusion proteins containing
deletions of each of the four blades in PEX9: GST-B1, GST-
B2, GST-B3, and GST-B4 (Fig. 5A). The purity of these
proteinswas confirmed by SDS-PAGE analyses (Fig. 5A). These
four fusion proteins supported adhesion of MEC-1 cells (Fig.
5B), confirming the retention of their biological activity. GST-
B1, GST-B2, GST-B3, and GST-B4 proteins were then
tested as inhibitors of DQ-gelatin degradation by MMP-9. Fig.
5C shows that deletion of the B1 or B4 blades reduced the inhib-
itory ability of PEX9 from 25% to 13 and 10%, respectively,
whereas deletion of B2 or B3 had no effect.
Further Characterization of the Inhibitory Activity of Blades
B1 and B4 on Gelatin Degradation byMMP-9—Having identi-
fied blades 1 and 4 as the regions in PEX9 with inhibitory activ-
ity, we tested whether this activity was dose-dependent. The
DQ-gelatin degradation assay was used for this purpose. Acti-
vated MMP-9 was incubated with constant concentrations of
DQ-gelatin (20g/ml) in the absence or presence of increasing
concentrations of GST-PEX9, GST-B1, or GST-B4. All three
proteins inhibited gelatinolysis in a dose-dependent manner,
FIGURE 2.Role ofGST-PEX9on thedegradationofMMP-9 andMMP-2 substrates.A, 1 nMMMP-9was incubatedwith 2.5g/mlDQ-peptide in the absence
or presence of 0.4M GST-PEX9. The conversion of DQ-peptides into fluorogenic peptides wasmonitored on a fluorescence reader. The fluorescence and the
maximal velocityof theenzyme (initial velocity at the10-min readpoint) fromthe sameexperiment are shown in the twographs.B, preparationsof 2gof actin
or B-crystallin (B-Cryst) were incubated with active MMP-9 (actMMP-9) in the absence or presence of 0.4 M GST-PEX9. After the indicated times at 37 °C,
cleaved proteins were analyzed by SDS-PAGE and Coomassie Blue staining. C andD, velocity of the degradation of DQ-collagen byMMP-9 (C) and DQ-gelatin
by MMP-2 (D). Maximum velocity (initial velocity time point at 10 min) was normalized to 100, and enzymes were used at 0.1 nM. AU, arbitrary units.
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and GST-B4 was the most effective at all concentrations tested
(Fig. 5D). To confirm these results, we tested whether these
proteins bound to gelatin using ELISAs. Fig. 5E shows that
GST-PEX9, GST-B1, and GST-B4 bound to gelatin, whereas
GST,GST-B2, andGST-B3 did not. These data therefore estab-
lished the identity and specificity of blades 1 and 4 of PEX9 as
inhibitors of gelatin degradation.
To place these biochemical findings in a biological context,
we analyzed the inhibitory capacity of the PEX9 proteins on
cell-induced degradation of FITC-gelatin. For these experi-
ments, we used the leukemic cell lineMEC-1, stably transfected
with MMP-9 (MMP-9–MEC-1 cells) (19). We previously
showed that these cells produce high amounts ofMMP-9, most
of which is in an active form (19). 1 105 MMP-9 transfected
MEC-1 cells were incubated with FITC-gelatin in the presence
or absence of theGST-PEX9 variants, and the resulting fluores-
cence was determined after 24 h. Fig. 5F shows that GST-PEX9
significantly inhibited FITC-gelatin degradation by 34%, com-
pared with the control cells with no inhibitor. In agreement
with the results obtained with purifiedMMP-9, recombinant
proteins containing blades B1 and/or B4 inhibited the deg-
radation of gelatin by MMP-9–MEC-1 cells, whereas
GST-B2 and GST-B3 had no effect (Fig. 5F). Altogether,
these results established that blade 4 and to a lesser extent
FIGURE 3. Effect of the B1B2 and B3B4 regions of PEX9 on the inhibition of gelatin degradation by MMP-9. A, schematic drawing of the truncated
GST-B1B2 andGST-B3B4 fusionproteins prepared in this study. B, SDS-PAGE analysis of the purifiedGST fusionproteins, visualized byCoomassie Blue staining.
C, representativegelatin zymography analysis using20ngof proMMP-9 andwithorwithout the indicatedproteins (0.4Meach).D, 60 nMofMMP-9was added
to FITC-gelatin-coated plates in the absence or presence of 0.4 M of the indicated proteins. After 24 h at 37 °C, fluorescence was determined, and control
valueswere normalized to 100. E, effect of the indicated proteins on the conversion of DQ-gelatin into fluorogenic gelatin. The lines show themaximal enzyme
velocity evolution as a function of the amount of substrate. The bars represent standard deviation. *, p 0.05; **, p 0.01. AU, arbitrary units.
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blade 1 are the regions responsible for the inhibitory role of
PEX9 in gelatin degradation.
Discussion
We have studied the effect of human PEX9 on MMP-9 pro-
teolysis on several substrates. We report that PEX9 inhibits the
degradation of gelatin but not of otherMMP-9 substrates. This
was due to the sequestration of gelatin by PEX9, which is there-
fore a binding competitor, but not an antagonist, of MMP-9.
TheMMP family has been studied formany years, because of
their role in many physiological and pathological processes. At
first, the scientific community focused on the catalytic roles of
FIGURE 4. Blades B1 and B4 of PEX9 inhibit gelatin degradation by MMP-9. A, schematic drawing of the truncated recombinant GST fusion proteins. B,
SDS-PAGE analysis of the purified proteins shown in A. C, BCECF-AM-labeledMEC-1 cells were added to wells coated with the indicated proteins (0.4M), and
adhesion was quantitated as explained. D, MEC-1 cells were incubated for 30 min with or without the indicated proteins (0.8 M) and analyzed by flow
cytometry using anti-GST antibodies. E, representative gelatin zymography analysis of 20 ng of purified recombinant proMMP-9 in the presence or absence of
the indicated proteins. The values (arbitrary units) represent the averages of three different experiments. F, 60 nM ofMMP-9was added to FITC-gelatin-coated
plates in the absence or presence of the indicated proteins. After 24 h, the fluorescence was determined. G, effect of the indicated proteins on the conversion
ofDQ-gelatin into fluorogenic gelatin. Thegraph represents themaximal enzymevelocity evolution as a functionof the amountof substrate. *,p0.05; **,p
0.01. AU, arbitrary units.
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these molecules, and most efforts were concentrated on devel-
oping inhibitors of the catalytic activity. The main problem
with this was that the amino acid sequences of the catalytic
domain are highly conserved among all MMPs and even within
the ADAM and ADAMTS family (25, 26). Therefore, most of
the inhibitorswere not specific, inhibiting a range ofMMPs and
resulting in side effects. In recent years, it was demonstrated
that most MMPs also have noncatalytic functions (27) and can
act like ligands (28) or even like transcription factors (29, 30).
Because of the failure of first generation MMP inhibitors, the
search is now open toward inhibitors that target specific func-
tions of one or more MMPs. More detailed information about
the structure and function of singleMMP domains (exosites) is
therefore needed (25, 31).
The hemopexin domain of the MMPs is the main domain
that drives the noncatalytic functions, because of its ability to
interact with substrates, receptors, and inhibitors (11–13). For
example, in chronic lymphocytic leukemia cells, PEX9 candrive
intracellular signaling and survival independently of other
MMP-9 domains (14, 28). Given the lower amino acid sequence
homology in the hemopexin domains than in other domains
among MMPs, we suggest that targeting this domain may be a
useful and more specific approach to prevent MMP-9-medi-
ated pathological functions. Indeed, strategies aimed at block-
ing the interaction of PEXwith individualmolecules are already
in progress. For example, we recently identified the sequences
in PEX9 responsible for the interaction of proMMP-9 with
CD44 (FDAIAEIGNQLYLFKDGKYW, blade 1) and 41
integrin (FPGVPLDTHDVFQYREKAYFC, blade 4) in chronic
lymphocytic leukemia cells (14, 23). Likewise, active sequences
in blades 1 and 4 of MMP-14 were identified and shown to
inhibit carcinoma cell migration, tumor metastasis, and angio-
genesis (32).
In the present report, we have characterized a different func-
tion of PEX9, namely its ability to block gelatin and collagen
degradation byMMP-9. Interestingly, this activity also involved
structural blades 1 and 4, highlighting the importance of these
regions inmany PEX9 functions. Our data clearly show that the
inhibitory function of PEX9 did not apply to the degradation of
otherMMP-9 substrates, such as a small fluorogenic peptide or
B-crystallin. This, together with the fact that PEX9 also abro-
gated gelatinolysis by MMP-2, indicates that PEX9 is not an
FIGURE 5. Further characterization of the effect of PEX9 blades B1 or B4 on gelatin degradation by MMP-9. A, schematic drawing of the truncated GST
fusion proteins lacking specific blades of PEX9 and SDS-PAGE analysis of the purified proteins. B, cell adhesion of BCECF-AM-labeled MEC-1 cells to the
indicated proteins (all at 0.4 M). C, effect of the indicated mutant proteins on the conversion of DQ-gelatin into fluorogenic gelatin. The maximal enzyme
velocity (initial velocity t 10 min) evolution as a function of the amount of substrate is shown. D, dose-dependent inhibition of MMP-9-driven DQ-gelatin
degradation by the indicated recombinant proteins. The graph shows the inhibition of the maximal velocity in each experiment, after normalizing control
signals to 100. E, binding of the indicated proteins to 5g of immobilized gelatin determined by ELISA. F, effect of PEX9-derived proteins on the degradation
of FITC-gelatin by MMP-9–MEC-1 cells. 1 105 MMP-9–MEC-1 cells were added to 96-well plates coated with FITC-gelatin, in the absence or presence of the
indicated proteins. After 24 h at 37 °C,wellswerewashed, and the remaining fluorescencewas determined. The values fromcontrolwells (FITC coatedwithout
cells) were normalized to 100. The bars represent standard deviation. AU, arbitrary units. *, p 0.05; **, p 0.01.
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antagonist ofMMP-9 catalytic function, as previously proposed
(17). Instead, PEX9 blocks gelatin degradation because it spe-
cifically binds to gelatin and probably not to otherMMP-9 sub-
strates. Indeed, murine PEX9 was previously shown to bind to
gelatin, and the binding parameters have been reported (17, 18).
Using recombinant proteins that lack or contain specific blades
of human PEX9, in the present study we have extended the
binding studies and have identified blade 4 and, to a lesser
extent, blade 1 as the structural modules in PEX9 that bind to
gelatin and inhibit MMP-9 gelatinolysis.
Degradation and remodeling of the extracellular matrix,
mostly carried out byMMPs, play crucial roles in normal devel-
opment but also in the migration and metastasis of cancer cells
(33, 34). The extracellular matrix is therefore a dynamic struc-
ture whose components interact with specific integrin recep-
tors and trigger intracellular signaling and cell responses. Con-
sequently, depending on the composition of the extracellular
matrix, these ligand-receptor interactions will induce different
signaling, directly affecting cell behavior (35). To fully under-
stand the behavior of different cell types, including metastatic
cancer cells, new probes and also extracellular matrix mole-
cules may lead to the development of new drugs against cancer.
Until now, the research focus was to target the malignant cells
and theMMPs,which degrade the extracellularmatrix. Itmight
be equally important to try to block specific components of this
matrix, such as gelatin. Therefore the PEX9blades, generated in
this study, may become useful probes to study gelatinolysis
and/or serve to generate specific inhibitors of gelatinolysis.
Because this approach specifically targets gelatin catalysis, it
might also serve to block the migration of metastatic cancer
cells and of leukocytes in pathological inflammations. In sum-
mary, the present study helps to understand how MMP-9 and
gelatin interact with each other and points toward new direc-
tions to develop new inhibitors of specific MMP functions.
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